<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04498780</url>
  </required_header>
  <id_info>
    <org_study_id>DL-L-20005_V1.4</org_study_id>
    <nct_id>NCT04498780</nct_id>
  </id_info>
  <brief_title>Hemodynamic Effects of ARNI on Noninvasive Pressure-volume Analysis in Patients With Chronic Heart Failure</brief_title>
  <acronym>ARNI-PVA</acronym>
  <official_title>Hemodynamic Effects of Angiotensin Receptor Neprilysin Inhibition on Noninvasive Pressure-volume Analysis in Patients With Heart Failure With Reduced Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sacubitril-Valsartan reduced heart failure hospitalizations and cardiovascular mortality&#xD;
      compared to enelapril in chronic heart failure. Furthermore, quality of life is improved. The&#xD;
      decrease of NT-proBNP levels during Sacubitril-Valsartan treatment is associated with reverse&#xD;
      left ventricular remodeling and improved left ventricular systolic function. However, the&#xD;
      underlying mechanisms that contribute to these symptomatic and prognostic benefits are&#xD;
      largely unknown. The aim of this study is to evaluate left ventricular hemodynamics in&#xD;
      patients treated with Sacubitril-Valsartan using non-invasive pressure-volume analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Left ventricular contractility, afterload and ventricular-arterial coupling</measure>
    <time_frame>6 months</time_frame>
    <description>Change of end-systolic elastance (Ees), arterial elastance (Ea) and ventricular-arterial coupling (Ea/Ees)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic LV function, symptom status and biomarkers</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Echocardiography: Left ventricular (LV) remodeling und function (LVEDV, LVESV, LVEF, GLS), diastolic LV function (LAESV, E/e', LVEDP)&#xD;
Symptoms: NYHA functional class, 6 minute walk test&#xD;
Biomarker: NT-proBNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular contractility, afterload and ventricular-arterial coupling</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Change of end-systolic elastance (Ees), arterial elastance (Ea) and ventricular-arterial coupling (Ea/Ees)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Load-independent parameters of systolic and diastolic LV function, myocardial work indices</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Peak power index (PPI)&#xD;
Preload-recruitable stroke work (PRSW)&#xD;
End-systolic meridional wall stress (EsMWS)&#xD;
Total peripheral resistance (TPR)&#xD;
LV end-systolic pressure (LVEDP)&#xD;
LV end-diastolic pressure-volume relationship (LVEDPVR)&#xD;
Pressure-strain loops</description>
  </other_outcome>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubitril-Valsartan</intervention_name>
    <description>Observational study during the clinically indicated treatment</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with symptomatic heart failure (NYHA functional class II to IV) and reduced&#xD;
        ejection fraction (LVEF≤40%) with clinical indication for therapy with Sacubitril-Valsartan&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic heart failure (NYHA functional class II to IV)&#xD;
&#xD;
          -  Reduced LV ejection fraction (≤ 40%)&#xD;
&#xD;
          -  Clinical indication for therapy with Sacubitril-Valsartan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  catecholamine therapy at inclusion&#xD;
&#xD;
          -  existing therapy with Sacubitril-Valsartan&#xD;
&#xD;
          -  planned cardiac resynchronization therapy (CRT) within 6 months; inclusion at least 3&#xD;
             months after CRT&#xD;
&#xD;
          -  planned mitral or aortic valve procedure within 6 months; inclusion at least 3 months&#xD;
             after valve procedure&#xD;
&#xD;
          -  participation in another randomized heart failure trial&#xD;
&#xD;
          -  severe aortic or mitral valve lesion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Lavall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leipzig</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Lavall, MD</last_name>
    <phone>+493419712650</phone>
    <email>Daniel.Lavall@medizin.uni-leipzig.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tina Stegmann, MD</last_name>
    <phone>+493419712650</phone>
    <email>Tina.Stegmann@medizin.uni-leipzig.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Lavall, MD</last_name>
      <phone>+493419712650</phone>
      <email>Daniel.Lavall@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Tina Stegmann, MD</last_name>
      <phone>+493419712650</phone>
      <email>Tina.Stegmann@medizin.uni-leipzig.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kardiopraxis Schirmer</name>
      <address>
        <city>Kaiserslautern</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan H Schirmer, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2020</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Daniel Lavall</investigator_full_name>
    <investigator_title>Dr. med. Daniel Lavall</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Sacubitril and valsartan sodium hydrate drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

